Breelyn Wilky, MD, explains when patients with gastrointestinal stromal tumor should be referred for clinical trials.

The case of generic imatinib demonstrates several potential barriers to effective generic price competition for specialty prescription drugs, including fewer market entrants, smaller-than-expected ...

SH-110, a liquid cancer treatment for glioma, earned orphan drug status from the FDA, helping patients who struggle to ...

"Imcranib 100", the first targeted cancer drug in tablet form developed and produced in Thailand, is the result of the research and development work of Her Royal Highness Princess Chulabhorn ...

Just before President Trump pushed her out at the behest of his corporate donors, former Federal Trade Commission chairwoman Lina Khan released a damning report about the most rapacious and ...

Delhi has long stood as a beacon of modern healthcare. The national capital is home to gleaming hospitals, internationally ...

Thailand has produced its first locally developed targeted therapy pill for cancer treatment. Imcranib 100 is the result of ...

Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug ...

Aussies could be left hundreds of dollars out-of-pocket as Donald Trump threatens 200 per cent tariffs on Australian ...

Cogent Biosciences, Inc. is a Strong Buy after trial data for bezuclastinib & market growth potential in systemic ...

DelveInsight's, “Gastrointestinal Stromal Tumors Pipeline Insight 2025” report provides comprehensive insights about 25+ ...

Italy’s Robin Foà, MD, an iconic European clinician-researcher, has been at forefront of hematology’s transformation for half ...